You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Myeloma: diagnosis and management

  • NICE guideline
  • Reference number: NG35
  • Published:  10 February 2016
  • Last updated:  25 October 2018

Register as a stakeholder

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download (PDF)
  • About this information
  • Myeloma
  • Your care team
  • Information and support
  • Tests for myeloma
  • Initial treatment for myeloma
  • Treatment for primary plasma cell leukaemia
  • Further treatment for myeloma
  • Kidney problems
  • Bone problems
  • Other problems caused by myeloma
  • Follow-up checks
  • Terms explained
  • Sources of advice and support
  • Other NICE guidance

Other NICE guidance

  • Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (2015) NICE technology appraisal guidance 338

  • Neuropathic pain in adults: pharmacological management in non-specialist settings (2013) NICE guideline CG173

  • Osteoporosis: assessing the risk of fragility fracture (2012) NICE guideline CG146

  • Palliative care for adults: strong opioids for pain relief (2012) NICE guideline CG140

  • Patient experience in adult NHS services (2012) NICE guideline CG138

  • Bortezomib and thalidomide as first treatments for multiple myeloma (2011) NICE technology appraisal guidance 228

  • Lenalidomide for multiple myeloma in people who have had previous treatment (2009) NICE technology appraisal guidance 171

  • Metastatic spinal cord compression in adults: diagnosis and management (2008) NICE guideline CG75

  • Bortezomib monotherapy for relapsed multiple myeloma (2007) NICE technology appraisal guidance 129

  • Improving outcomes in children and young people with cancer (2005) NICE cancer service guidance 7

  • Improving outcomes in haematological cancers (2003) NICE cancer service guidance 3

ISBN: 978-1-4731-1660-3

This page was last updated: 25 October 2018


Previous page Sources of advice and support
Back to top